Cargando…
Anti Diabetic effect of CL 316,243 (A β3-Adrenergic Agonist) by Down Regulation of Tumour Necrosis Factor (TNF-α) Expression
OBJECTIVE: Obesity is a risk factor for the development of insulin resistance and is one of the most important contributors to the pathogenesis of type2 diabetes, which acts mainly through the secretion of adipokines such as TNF-α that may influence insulin sensitivity. TNF-α affects many aspects of...
Autores principales: | Ghorbani, Masoud, Shafiee Ardestani, Mehdi, Gigloo, Sedigheh Hatami, Cohan, Reza Ahangari, Inanlou, Davoud Nouri, Ghorbani, Peyman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464262/ https://www.ncbi.nlm.nih.gov/pubmed/23056223 http://dx.doi.org/10.1371/journal.pone.0045874 |
Ejemplares similares
-
Apparent histological changes of adipocytes after treatment with CL 316,243, a β-3-adrenergic receptor agonist
por: Ghorbani, Masoud, et al.
Publicado: (2015) -
CL316,243, a β3-adrenergic receptor agonist, induces muscle hypertrophy and increased strength
por: Puzzo, Daniela, et al.
Publicado: (2016) -
The glucose lowering effects of CL 316,243 dissipate with repeated use and are rescued bycilostamide
por: Medak, Kyle D., et al.
Publicado: (2022) -
The beta-3 adrenergic agonist (CL-316,243) restores the expression of down-regulated fatty acid oxidation genes in type 2 diabetic mice
por: Kumar, Amit, et al.
Publicado: (2015) -
Adipose tissue hyaluronan production improves systemic glucose homeostasis and primes adipocytes for CL 316,243-stimulated lipolysis
por: Zhu, Yi, et al.
Publicado: (2021)